BMO Capital lowered the firm’s price target on Phathom Pharmaceuticals to $30 from $35 on slightly wider net loss than expected in Q4 but keeps an Outperform rating on the shares. The company’s key product Voquezna’s unique MoA as P-CAB is more potent alternative to standard-of-care PPIs, while the recent H. pylori approval and potential Erosive Esophagitis approval represent solid commercial opportunities, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PHAT:
- Phathom Pharmaceuticals expects cash to fund operations through 2024
- Phathom Pharmaceuticals reports Q4 EPS ($1.33), consensus ($1.35)
- Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- PHAT Nosedives on Vonoprazan Uncertainties
- Phathom Pharmaceuticals discloses FDA CRL on certain products
